Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06060873 · ClinicalTrials.gov registry record

MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial

A clinical trial, sponsored by University of Southern California.

Recruiting
Registry status
418
Enrollment target

NCT06060873 is a clinical trial that is actively recruiting participants, run by University of Southern California. The registered enrollment target is 418 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06060873 is actively recruiting participants, sponsored by University of Southern California.

RECRUITING
Registry status
418 participants
Enrollment target

Study Summary

This study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.

Interventions

  • OTHER Clinical Stage I Disease
  • OTHER Clinical Stage I with relapse, CSII Disease

Trial Details

FieldValue
Enrollment Target 418 participants
Start Date 2023-06-08
Est. Completion 2028-12-08

Sponsor

University of Southern California

617 total trials

What the Registry Record Tells You About NCT06060873

The ClinicalTrials.gov registry entry for NCT06060873 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Clinical Stage I Disease is the first listed.

NCT06060873 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06060873 about?

NCT06060873 is a clinical study titled "MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease Trial". This study evaluates the accuracy of blood-based biomarker testing to predict the presence of active testicular cancer.

What is the current status of trial NCT06060873?

This trial is currently recruiting. The enrollment target is 418 participants. The study started on 2023-06-08. Estimated completion is 2028-12-08.

What interventions are being tested in trial NCT06060873?

The interventions under investigation include: Clinical Stage I Disease (OTHER), Clinical Stage I with relapse, CSII Disease (OTHER).

Who is sponsoring clinical trial NCT06060873?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.